Nine-valent HPV Vaccine May Prevent Nearly 90 Percent of Cervical Cancers

October 1, 2014 Because nine human papillomavirus (HPV) subtypes were found to cause the majority of cervical precancers, a nine-valent HPV vaccine currently being investigated may be able to prevent more cervical cancers than current vaccines, according to research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. “We wanted to study how …

Gardasil Approved in Europe for the Prevention of Anal Cancer

The European Commission granted a new indication for Gardasil®, for the prevention of anal cancer and anal precancerous lesions caused by specific oncogenic HPV types in both females and males June 18, 2014 Sanofi Pasteur MSD announced today that the European Commission has granted marketing authorisation for the use of Gardasil for the prevention of anal precancerous lesions and anal …

Gardasil: CHMP Grants Positive Opinion for New Indication, for the Prevention of Anal Cancers and Anal Precancerous Lesions, in the European Union

European Committee for Medicinal Products for Human Use evaluated positively a new indication for the prevention of anal cancers and precancerous lesions for Gardasil April 30, 2014 Sanofi Pasteur MSD announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion for Gardasil® to be used for the prevention of anal precancerous …

Gardasil® 2-dose schedule approved in the European Union for children aged from 9 to 13 years

Alternative regimen for quadrivalent HPV vaccine now available for 9-13 year olds April 3, 2014 Sanofi Pasteur MSD announced today that the European Commission has granted marketing authorisation for a 2-dose schedule at 0 and 6 months in children aged from 9 to 13 years for its quadrivalent Human Papillomavirus (HPV) vaccine. Gardasil® is the only quadrivalent HPV vaccine and …

GAVI Alliance set to Support Plans to Vaccinate 1.5m Against Human Papillomavirus

March 8, 2014 The GAVI Alliance today announced that it will support vaccination programmes in Rwanda, Uganda and Uzbekistan aiming to protect 1.5 million girls against the cause of cervical cancer. The first Alliance-supported national rollouts of the vaccine, which protects against human papillomavirus (HPV), will begin in Uganda and Uzbekistan in 2015 while Rwanda will switch from a vaccine manufacturer’s donation …